Pharmacy news roundup

Here are links to pharmacy-related provider alerts from February:

• Changes to the management of oncology medical benefit drugs starting June 1 (PDF)
• Changes to the Oncology Value Management program starting April 1 (PDF)
• Tyenne will be preferred tocilizumab biosimilar product for most commercial members, starting June 1 (PDF)
• Alyglo, Amtagvi and Loqtorzi to have requirements for Blue Cross commercial URMBT members starting June 1 (PDF)
• Xbryk and Ospomyv to require prior authorization for most commercial members starting Feb. 28 (PDF)
• Update: Step therapy won’t be required for Darzalex Faspro (PDF)
• How to obtain CGM products for commercial and Medicare Advantage members (PDF)
• Rebyota and Ryoncil will have additional requirements for most commercial members starting March 31 (PDF)
• Trazimera to be preferred trastuzumab product for Medicare Advantage members starting May 12 (PDF)
• Avtozma to require prior authorization for most commercial members starting Feb. 20 (PDF)
• Ahzantive, Enzeevu, Epysqli and Pavblu to require prior authorization for Medicare Advantage members starting May 1 (PDF)
• Step therapy requirements added for Entyvio, Rystiggo, Vabysmo and Vyvgart for Medicare Advantage members starting May 1 (PDF)
• Update: Piasky and Tremfya to have a site-of-care requirement for most commercial members starting June 1 (PDF)

Tip: You can also subscribe to Provider Alerts Weekly to receive a weekly email with links to the previous week’s provider alerts.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.

Availity^® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.